[Drug-induced subacute cutaneous lupus erythematosus: repeated occurrence following treatment with terbinafine].
A woman developed subacute cutaneous lupus erythematosus (SCLE) in 1995 and 2013, each time 6 weeks after initiation of terbinafine therapy. Within the heterogeneous group of drug-induced SCLE terbinafine is considered the most common cause. The clinical, histopathological and laboratory findings of idiopathic and drug-induced SCLE are largely identical. The pathogenesis of drug-induced SCLE is not known. Cytotoxic and immunological mechanisms are considered likely. The treatment of drug-induced SCLE is discontinuation of the suspected drug. In addition, corticosteroids are recommended alone or in combination with chloroquine or hydroxychloroquine.